San Francisco-based biotechnology company Prellis Biologics has raised $8.7M in a Series A funding round. Holographic bioprinting is leading to new milestones and steps forward in 3D printed tissue and organs.
San Francisco-based biotechnology company Prellis Biologics has raised $8.7M in a Series A funding round. Holographic bioprinting is leading to new milestones and steps forward in 3D printed tissue and organs.